Key Points

  • HIMS) stock dropped 14.73% on July 29, 2026, after FTC announced lawsuit alleging the company shared medical data with Meta and Snap without proper disclosure
  • Investors who purchased shares between August 4, 2025 and July 29, 2026 have until November 2, 2026 to seek lead plaintiff status in the class action
  • The litigation exposes a critical gap between HIMS's public privacy commitments and actual practices, raising questions about management credibility and potential regulatory fines

Hims & Hers Health, Inc. (HIMS) is now fighting on two fronts: an aggressive FTC enforcement action alleging deceptive privacy practices and a securities class action lawsuit on behalf of shareholders who claim they were misled about how the company handles sensitive medical information. The July 29, 2026 announcement triggered an immediate 14.73% single-day selloff, erasing roughly $2.8 billion in market capitalization and signaling investor recognition of real legal and reputational damage.

What makes this case particularly damaging is the specificity of the FTC's allegations. The regulator didn't accuse HIMS of vague or theoretical privacy risks—it claimed the company systematically shared identifiable medical data (including data about users seeking treatments for erectile dysfunction, weight management, and dermatological conditions) with third-party advertisers including Meta Platforms and Snap Inc. for targeted advertising purposes. This wasn't a buried data broker arrangement; it was core to HIMS's advertising funnel and business model.

HIMS Privacy Scandal: What the Timeline Reveals

The structure of the securities lawsuit is particularly revealing about the investment case. The complaint covers the period from August 4, 2025 through July 29, 2026—a full eleven months during which HIMS maintained public statements about its privacy protections while allegedly engaging in the very conduct the FTC now alleges. This suggests a deliberate gap between public disclosure and actual practice, not a recent discovery or policy change.

Consider the competitive context: telemedicine companies like Amazon Pharmacy, CVS Health's telehealth offerings, and GoodRx have all faced increasing scrutiny on data practices. But HIMS marketed itself to price-sensitive, privacy-conscious consumers seeking convenient access to sensitive healthcare products. That positioning made privacy commitments a material part of the investment thesis. When those commitments prove hollow, the reputational cost far exceeds the immediate stock decline.

The FTC's allegation also creates operational ambiguity. If HIMS's advertising infrastructure has been built around real-time medical data sharing with Meta and Snap, unwinding that relationship (as the FTC will almost certainly demand) won't be a software update—it will require retooling the entire customer acquisition apparatus. That's a structural business model problem, not a compliance fix.

What HIMS Means for Investors in 2026

From a portfolio perspective, this lawsuit creates three distinct risk layers that won't resolve quickly. First, there's the regulatory penalty: FTC settlements for this type of data mishandling typically range from $10 million to $100 million depending on company size and violation severity. HIMS's 2026 market cap (now depressed) suggests a meaningful settlement could represent 2-5% of equity value. That's material but not catastrophic on its own.

The second risk is structural. If HIMS cannot leverage real-time medical data in its advertising operations, customer acquisition costs will spike. The company's gross margins depend on converting high-frequency digital marketing into subscription revenue. Losing the data advantage means higher CAC and longer payback periods on marketing spend. Wall Street will likely re-rate growth expectations downward if this advertising model is fundamentally compromised.

Third, and most damaging long-term, is credibility. Management credibility is the moat for a telemedicine company. When leadership oversees deceptive practices and doesn't proactively disclose them to investors, institutional shareholders—particularly ESG-focused allocators and fiduciaries—become skeptical of all forward guidance. Analyst coverage may become harder to maintain. The stock valuation multiple could contract independent of earnings changes.

For traders with existing positions, the November 2, 2026 lead plaintiff deadline creates a near-term catalyst window. Class action settlements typically resolve within 18-24 months, so expect regulatory clarity and financial impact by late 2027 or early 2028. That's a long overhang. For new investors, the risk-reward is asymmetrical: the stock has already priced in substantial downside (the 14.73% drop), but catalysts are all downside-skewed (larger FTC penalty, slower customer growth, analyst downgrades) with few near-term upside catalysts.

The Bottom Line on HIMS

Hims & Hers is not a company in terminal decline, but it is a company whose business model is under siege. The telemedicine sector itself remains structurally attractive—rising healthcare costs, chronic disease prevalence, and consumer preference for remote care are secular tailwinds. But HIMS's execution has exposed a fundamental tension between growth and governance. Fast-growing startups often cut corners on compliance; telemedicine companies operating in regulated healthcare should know better.

The stock may find a floor as institutional holders differentiate between the business fundamentals (which remain intact) and the governance crisis (which is real). But until the FTC settlement is announced and HIMS provides credible evidence that it has rebuilt customer acquisition on a sustainable, compliant basis, the risk-reward favors staying on the sidelines. The [insider trading tracker](/insider-trading) will likely show meaningful insider selling in coming quarters if executives expect further downside.

People Also Ask

Is HIMS stock a good buy after the FTC lawsuit?

Not yet. The stock has fallen sharply, but the full scope of the FTC penalty, customer acquisition impact, and margin compression remains uncertain. Wait for the FTC settlement to be announced and for management to provide updated guidance on advertising economics before re-entering the position. The risk-reward is better at lower prices or after regulatory clarity.

How much will the FTC fine HIMS for privacy violations?

FTC settlements for health data mishandling typically range from $10 million to $100 million depending on company size and repeat violations. HIMS, with a post-decline market cap around $18-20 billion, could reasonably face a $30-60 million penalty if the agency views this as particularly egregious. Watch the earnings calendar for management commentary on legal accruals.

What stocks are politicians buying in the healthcare sector amid HIMS scandal?

While what stocks are politicians buying is always relevant to institutional investors, the HIMS scandal hasn't yet triggered regulatory or legislative response at the congressional level. Focus instead on how traditional healthcare giants (UnitedHealth, CVS Health) are positioning against faster-growing but less-scrutinized telemedicine competitors. The data privacy issue may accelerate sector consolidation as larger players acquire smaller fintechs and impose compliance standards.

Explore more: HIMS Stock Analysis